

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**“ROTIGOTINE PATCH” APPROVED FOR MARKETING**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Rotigotine Patch” (brand name: 羅菲定®) developed by the Group has been approved by the National Medical Products Administration of China for marketing, for monotherapy for the symptoms and signs of early idiopathic Parkinson’s disease, or in combination with levodopa at various stages of the course of the disease.

The Parkinson’s disease is a common neurodegenerative disorder in middle-aged and elderly people. According to the “China Parkinson’s Disease Report 2025”, the number of existing number of Parkinson’s disease patients in China exceeds 5 million<sup>[1]</sup>. In addition to motor symptoms such as bradykinesia, muscle rigidity, resting tremor, and postural balance disorders, the disease is often accompanied by various non-motor symptoms such as olfactory disorders, abnormal sleep behavior, depression and anxiety, and constipation.

The root cause of Parkinson’s disease is the gradual apoptosis of nerve cells that produce dopamine in the substantia nigra region of the brain, which is currently incurable. As the disease progresses, patients need to rely entirely on drugs to supplement dopamine, and when the drug concentration fluctuates, there will be a “on-off” phenomenon: The “on-period” means that when the drug takes effect, the motor function of patients is improved, and physical activity is relatively free. The “off-period” means that when the efficacy of the drug weakens or disappears, the patients quickly experience limb stiffness and difficulty in movement, as if there were a power outage.

Rotigotine patch is a non-ergot dopamine receptor agonist that is administered transdermally. This method not only avoids the hepatic first-pass effect, but also has the characteristics of long acting and extended-release, which can maintain a stable drug concentration in blood for 24 hours. For patients with Parkinson's disease with "on-off phenomenon", the drug can significantly reduce the occurrence of "off-periods" and prolong the time of "on-periods", while reducing the risk of motor complications caused by pulsatile stimulation of dopamine receptors, thereby achieving smoother symptom control. In addition, the simple once-daily patch regimen is expected to greatly improve patients' compliance, and has significant advantages in patients with dysphagia, need for elective surgeries, or elderly and frail individuals. Rotigotine patch has been included in many guidelines and consensus such as the "Guidelines for the Treatment of Parkinson's Disease in China"<sup>[2]</sup>, and is recommended as an initial treatment option for patients in the early stage of young-onset Parkinson's disease.

Leveraging the Group's proprietary solvent-based transdermal patch platform, 羅菲定<sup>®</sup> is another significant achievement in transdermal treatments for neurological disorders, following the Alzheimer's disease therapy rivastigmine transdermal patch (蘇樂達<sup>®</sup>). In recent years, the Group has continued to upgrade its transdermal patch platform and successfully expanded its applications from non-steroidal anti-inflammatory and local anesthesia to the treatment of central nervous system diseases such as Alzheimer's disease and Parkinson's disease. At present, more than 10 patch products in the Group's pipeline are expected to be approved for marketing by 2030, further consolidating leading position of the Group in the field of transdermal patches.

Sources:

- [1] Wang Gang, Xu Gang, Xie Xinyi, etc. China Parkinson's Disease Report 2025. Journal of Neurology and Neurorehabilitation, 2025, 21(2): 63-98.
- [2] Parkinson's Disease and Movement Disorders Section of the Neurology Branch of the Chinese Medical Association, Parkinson's Disease and Movement Disorders Section of the Neurological Physicians Branch of the Chinese Medical Association. Guidelines for the Treatment of Parkinson's Disease in China (Fourth Edition). Chinese Journal of Neurology, 2020, 53(12):973-986.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 3 December 2025

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*